VTYX — Ventyx Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $584.43m
- $391.79m
- 56
- 20
- 98
- 61
Annual cashflow statement for Ventyx Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.2 | -83.7 | -108 | -193 | -135 |
| Depreciation | |||||
| Non-Cash Items | 21.2 | 41 | 14.7 | 20.5 | 14.5 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.812 | 4.02 | -5.16 | 5.81 | -10.6 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -6.2 | -38.6 | -98.8 | -167 | -131 |
| Capital Expenditures | 0 | -0.262 | -0.275 | -0.514 | -0.241 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -214 | -74.7 | 101 | -15.3 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | -214 | -74.9 | 101 | -15.5 |
| Financing Cash Flow Items | 6.13 | 0.45 | 0.267 | 0.25 | 0.205 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 6.13 | 324 | 168 | 53.3 | 122 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.065 | 70.5 | -5.97 | -12.3 | -24.3 |